These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 8174153)
1. Induction of rhythm abnormalities in the fetal rat heart. A tentative mechanism for the embryotoxic effect of the class III antiarrhythmic agent almokalant. Abrahamsson C; Palmer M; Ljung B; Duker G; Bäärnhielm C; Carlsson L; Danielsson B Cardiovasc Res; 1994 Mar; 28(3):337-44. PubMed ID: 8174153 [TBL] [Abstract][Full Text] [Related]
3. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes. Wettwer E; Grundke M; Ravens U Cardiovasc Res; 1992 Nov; 26(11):1145-52. PubMed ID: 1291093 [TBL] [Abstract][Full Text] [Related]
4. Developmental toxicity of the class III antiarrhythmic agent almokalant in mice. Adverse effects mediated via induction of embryonic heart rhythm abnormalities. Sköld AC; Danielsson BR Arzneimittelforschung; 2000 Jun; 50(6):520-5. PubMed ID: 10918943 [TBL] [Abstract][Full Text] [Related]
5. Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK block and lack of reverse use dependence in cat ventricular myocytes. Spinelli W; Moubarak IF; Parsons RW; Colatsky TJ Cardiovasc Res; 1993 Sep; 27(9):1580-91. PubMed ID: 8287434 [TBL] [Abstract][Full Text] [Related]
6. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle. Marschang H; Beyer T; Karolyi L; Kübler W; Brachmann J Cardiovasc Drugs Ther; 1998 Dec; 12(6):573-83. PubMed ID: 10410827 [TBL] [Abstract][Full Text] [Related]
7. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Nakaya H; Tohse N; Takeda Y; Kanno M Br J Pharmacol; 1993 May; 109(1):157-63. PubMed ID: 7684298 [TBL] [Abstract][Full Text] [Related]
8. Lidocaine and nisoldipine attenuate almokalant-induced dispersion of repolarization and early afterdepolarizations in vitro. Abrahamsson C; Carlsson L; Duker G J Cardiovasc Electrophysiol; 1996 Nov; 7(11):1074-81. PubMed ID: 8930739 [TBL] [Abstract][Full Text] [Related]
9. Electrophysiological, rate dependent, and autonomic effects of the class III antiarrhythmic almokalant after myocardial infarction in the pig. Tuininga YS; De Langen CD; Crijns HJ; Wiesfeld AC; Mook PH; Bel KJ; Lie KI Pacing Clin Electrophysiol; 1996 May; 19(5):802-10. PubMed ID: 8734747 [TBL] [Abstract][Full Text] [Related]
10. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Wellfelt K; Sköld AC; Wallin A; Danielsson BR Reprod Toxicol; 1999; 13(2):93-101. PubMed ID: 10213516 [TBL] [Abstract][Full Text] [Related]
11. Selective Ik blocker almokalant exhibits class III--specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings. Darpö B; Vallin H; Almgren O; Bergstrand R; Insulander P; Edvardsson N J Cardiovasc Pharmacol; 1995 Oct; 26(4):530-40. PubMed ID: 8569212 [TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation. Hoffmeister HM; Beyer ME; Seipel L Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409 [TBL] [Abstract][Full Text] [Related]
13. Rate-dependent class III antiarrhythmic action, negative chronotropy, and positive inotropy of a novel Ik blocking drug, UK-68,798: potent in guinea pig but no effect in rat myocardium. Tande PM; Bjørnstad H; Yang T; Refsum H J Cardiovasc Pharmacol; 1990 Sep; 16(3):401-10. PubMed ID: 1700210 [TBL] [Abstract][Full Text] [Related]
14. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Abrahamsson C; Duker G; Lundberg C; Carlsson L Cardiovasc Res; 1993 May; 27(5):861-7. PubMed ID: 8348585 [TBL] [Abstract][Full Text] [Related]
15. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations. Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427 [TBL] [Abstract][Full Text] [Related]
16. Stage-specific skeletal and visceral defects of the I(Kr)-blocker almokalant: further evidence for teratogenicity via a hypoxia-related mechanism. Sköld AC; Wellfelt K; Danielsson BR Teratology; 2001 Dec; 64(6):292-300. PubMed ID: 11754171 [TBL] [Abstract][Full Text] [Related]
17. Dofetilide: a review of its use in atrial fibrillation and atrial flutter. McClellan KJ; Markham A Drugs; 1999 Dec; 58(6):1043-59. PubMed ID: 10651390 [TBL] [Abstract][Full Text] [Related]
18. Membrane activity of class III antiarrhythmic compounds; a comparison between ibutilide, d-sotalol, E-4031, sematilide and dofetilide. Lee KS; Tsai TD; Lee EW Eur J Pharmacol; 1993 Mar; 234(1):43-53. PubMed ID: 8472760 [TBL] [Abstract][Full Text] [Related]
19. Electropharmacology of dofetilide, a new class III agent, in anaesthetised dogs. Gwilt M; Blackburn KJ; Burges RA; Higgins AJ; Milne AA; Solca AM Eur J Pharmacol; 1992 May; 215(2-3):137-44. PubMed ID: 1396982 [TBL] [Abstract][Full Text] [Related]
20. Identification and characteristics of delayed rectifier K+ current in fetal mouse ventricular myocytes. Wang L; Duff HJ Am J Physiol; 1996 Jun; 270(6 Pt 2):H2088-93. PubMed ID: 8764260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]